Flerie
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.
NET ASSET VALUE – 31 January 2025
MARKN.
On the 31 January 2025 Flerie AB's Net Asset Value (NAV) was SEK 4,211 million and NAV per share was SEK 53.94.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Prokarium | 42% | 482 | 6.18 | 11.5% |
| Xspray Pharma | 18% | 225 | 2.89 | 5.4% |
| KAHR Medical | 31% | 208 | 2.67 | 5.0% |
| Empros Pharma | 79% | 204 | 2.62 | 4.9% |
| Atrogi | 37% | 176 | 2.25 | 4.2% |
| Lipum | 57% | 166 | 2.13 | 3.9% |
| Xintela | 61% | 163 | 2.09 | 3.9% |
| Microbiotica | 10% | 137 | 1.76 | 3.3% |
| Geneos Therapeutics | 12% | 106 | 1.36 | 2.5% |
| Toleranzia | 66% | 105 | 1.35 | 2.5% |
| Mendus | 24% | 86 | 1.10 | 2.0% |
| AnaCardio | 17% | 69 | 0.89 | 1.6% |
| EpiEndo Pharmaceuticals | 9% | 57 | 0.73 | 1.4% |
| Vitara Biomedical | 10% | 55 | 0.71 | 1.3% |
| Synerkine Pharma | 43% | 53 | 0.68 | 1.3% |
| Egetis Therapeutics | 2% | 36 | 0.46 | 0.9% |
| Buzzard Pharmaceuticals | 14% | 29 | 0.37 | 0.7% |
| Sixera Pharma | 24% | 27 | 0.35 | 0.6% |
| Alder Therapeutics | 21% | 17 | 0.22 | 0.4% |
| Amarna Therapeutics | 58% | 12 | 0.15 | 0.3% |
| Strike Pharma | 16% | 9 | 0.11 | 0.2% |
| Total | 2,423 | 31.04 | 57.5% | |
| Commercial Growth | ||||
| NorthX Biologics | 92% | 189 | 2.42 | 4.5% |
| Symcel | 31% | 174 | 2.23 | 4.1% |
| Nanologica | 43% | 82 | 1.05 | 1.9% |
| Provell Pharmaceuticals* | 72% | 81 | 1.04 | 1.9% |
| Chromafora | 31% | 73 | 0.93 | 1.7% |
| A3P Biomedical | 8% | 46 | 0.59 | 1.1% |
| Frontier Biosolutions | 2% | 19 | 0.24 | 0.5% |
| Bohus Biotech | 45% | 17 | 0.21 | 0.4% |
| Total | 680 | 8.71 | 16.2% | |
| Limited Partnerships, total | 97 | 1,24 | 2,3% | |
| Assets related to Portfolio companies | 217 | 2.77 | 5.1% | |
| Other assets and liabilities | 794 | 10.17 | 18.9% | |
| Net asset value | 4,211 | 53.94 | 100.0% | |
* indirect shares in Provell Pharmaceuticals
| Datum | 2025-02-05, kl 08:00 |
| Källa | MFN |